Pub Date : 2026-02-01Epub Date: 2025-09-13DOI: 10.1016/j.apsb.2025.09.015
Jimei Liu, Ridao Chen, Min Zhang, Yangyang Duan, Keping Feng, Songyang Sui, Yaotian Han, Kebo Xie, Jun Wu, Haibo Yu, Dawei Chen, Jungui Dai
Phenylspirodrimanes are a class of structurally diverse meroterpenoids, including the bioactive dimer stachybocin A (1) and the high-reactivity monomer stachybotrydial (2), which are isolated from the genus Stachybotrys. Whereas the biosynthetic pathway of these phenylspirodrimane meroterpenoids has remained elusive. Herein, we deciphered the complete biosynthetic pathway of 2 with unprecedented two gene clusters and five discrete genes by genome mining, gene inactivation, heterologous expression, biochemical experiments, and especially combining with transcriptome-based hierarchical clustering and expression correlation analyses. Totally, 11 genes for the phenylspirodrimane core skeleton formation, 8′-methyl oxidation, and 3-OH epimerization were efficiently discovered and functionally characterized. Notably, these biosynthetic genes are distributed across seven distinct regions, with a rare combination of multiple gene clusters and genes outside the clusters. Bioactivity assays revealed that four intermediates 6−8, and 9a exhibited significant inhibitory effect on the inactivated state hNaV1.2 channels with IC50 values of 0.15, 0.04, 0.28, and 1.91 μmol/L, respectively. These findings expand our understanding of phenylspirodrimane-type meroterpenoid biosynthesis and underscore the utility of transcriptome-based hierarchical clustering and expression correlation analyses for identifying unclustered biosynthetic genes in fungi.
{"title":"Complete biosynthesis of phenylspirodrimanes with unclustered genes in Stachybotrys chartarum","authors":"Jimei Liu, Ridao Chen, Min Zhang, Yangyang Duan, Keping Feng, Songyang Sui, Yaotian Han, Kebo Xie, Jun Wu, Haibo Yu, Dawei Chen, Jungui Dai","doi":"10.1016/j.apsb.2025.09.015","DOIUrl":"10.1016/j.apsb.2025.09.015","url":null,"abstract":"<div><div>Phenylspirodrimanes are a class of structurally diverse meroterpenoids, including the bioactive dimer stachybocin A (<strong>1</strong>) and the high-reactivity monomer stachybotrydial (<strong>2</strong>), which are isolated from the genus <em>Stachybotrys</em>. Whereas the biosynthetic pathway of these phenylspirodrimane meroterpenoids has remained elusive. Herein, we deciphered the complete biosynthetic pathway of <strong>2</strong> with unprecedented two gene clusters and five discrete genes by genome mining, gene inactivation, heterologous expression, biochemical experiments, and especially combining with transcriptome-based hierarchical clustering and expression correlation analyses. Totally, 11 genes for the phenylspirodrimane core skeleton formation, 8′-methyl oxidation, and 3-OH epimerization were efficiently discovered and functionally characterized. Notably, these biosynthetic genes are distributed across seven distinct regions, with a rare combination of multiple gene clusters and genes outside the clusters. Bioactivity assays revealed that four intermediates <strong>6</strong>−<strong>8</strong>, and <strong>9a</strong> exhibited significant inhibitory effect on the inactivated state hNa<sub>V</sub>1.2 channels with IC<sub>50</sub> values of 0.15, 0.04, 0.28, and 1.91 μmol/L, respectively. These findings expand our understanding of phenylspirodrimane-type meroterpenoid biosynthesis and underscore the utility of transcriptome-based hierarchical clustering and expression correlation analyses for identifying unclustered biosynthetic genes in fungi.</div></div>","PeriodicalId":6906,"journal":{"name":"Acta Pharmaceutica Sinica. B","volume":"16 2","pages":"Pages 966-978"},"PeriodicalIF":14.6,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146177210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-01Epub Date: 2025-10-24DOI: 10.1016/j.apsb.2025.10.025
Tuo Wang , Dongsheng Zhang , Chi Jin , Hengjie Xu , Hongxu Nie , Ye Wang , Chuan Zhang , Yifei Feng , Junwei Tang , Yueming Sun
Metabolic reprogramming is a notable hallmark of cancer biology, especially aerobic glycolysis. Some clinical trials attempt to target cancer metabolism to develop therapeutic agents. However, the results have been not satisfactory. Here, we report that REEP6 is significantly upregulated and promotes glycolysis and tumorigenesis in CRC. Moreover, REEP6, as a molecular scaffolder, bridges the PRMT5–PGAM1 complex, which enhances the PRMT5-mediated symmetric dimethylarginine (SDMA) of PGAM1 at R40. The methylated PGAM1 possesses dramatically enhanced enzymatic activity and therefore boosts glycolytic flux in CRC cells. More than that, our results showed that combined treatment with specific shRNA and inhibitors exhibits synergistic anti-tumor efficacy in CRC, which may shed light on the development of a promising therapy in CRC.
{"title":"REEP6 promotes colorectal cancer glycolysis and tumorigenesis through PRMT5-mediated PGAM1 arginine methylation","authors":"Tuo Wang , Dongsheng Zhang , Chi Jin , Hengjie Xu , Hongxu Nie , Ye Wang , Chuan Zhang , Yifei Feng , Junwei Tang , Yueming Sun","doi":"10.1016/j.apsb.2025.10.025","DOIUrl":"10.1016/j.apsb.2025.10.025","url":null,"abstract":"<div><div>Metabolic reprogramming is a notable hallmark of cancer biology, especially aerobic glycolysis. Some clinical trials attempt to target cancer metabolism to develop therapeutic agents. However, the results have been not satisfactory. Here, we report that REEP6 is significantly upregulated and promotes glycolysis and tumorigenesis in CRC. Moreover, REEP6, as a molecular scaffolder, bridges the PRMT5–PGAM1 complex, which enhances the PRMT5-mediated symmetric dimethylarginine (SDMA) of PGAM1 at R40. The methylated PGAM1 possesses dramatically enhanced enzymatic activity and therefore boosts glycolytic flux in CRC cells. More than that, our results showed that combined treatment with specific shRNA and inhibitors exhibits synergistic anti-tumor efficacy in CRC, which may shed light on the development of a promising therapy in CRC.</div></div>","PeriodicalId":6906,"journal":{"name":"Acta Pharmaceutica Sinica. B","volume":"16 2","pages":"Pages 948-965"},"PeriodicalIF":14.6,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146177319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-01Epub Date: 2025-11-13DOI: 10.1016/j.apsb.2025.11.012
Mengwan Jiang , Mingyue Chen , Wen Zou , Yingxin Xie , Jinjin Shi , Junjie Liu , Aibing Chen , Xiu Zhao
Studies have shown that radiotherapy (RT) has powerful immune-stimulating effects. However, RT-mediated distal tumor regression is rare in clinical practice. Here, with an animal experimental model, we found that RT shaped an immunosuppressive landscape characterized by a high-influx of myeloid-derived suppressor cells (MDSCs), and the induction of immunologically silent tumor apoptosis, hindering the efficacy of radioimmunotherapy. To address this issue, we developed a spatiotemporally controlled nanomedicine for remodeling the immunosuppressive tumor microenvironment (TME) post-RT. Decitabine (DAC)-loaded ferritin (Ft) were crosslinked via an azobenzene linker, and meanwhile encapsulated with all-trans retinoic acid (ATRA) to construct a Ft@DAC@ATRA nanoassembly (denoted as FD@ATRA), which dissociated into monodispersive Ft@DAC units in hypoxia TME. The released ATRA could eliminate immunosuppressive MDSCs, and meanwhile Ft@DAC selectively induced immunogenic pyroptosis of the tumor by targeting the transferrin receptor 1 overexpressed on the tumor to effectively activate CD8+ T cells. FD@ATRA treatment reshaped the tumor immune landscape post-RT with an increase of 16.8% in tumor-infiltrating IFN-γ+CD8+ T cells. Moreover, FD@ATRA-enhanced RT remained effective in large, treatment-resistant tumors, and the inhibition rate of FD@ATRA-enhanced RT on distant tumors improved by 47% compared to the RT group alone, providing an effective therapeutic approach to improve the clinical outcomes of radioimmunotherapy.
{"title":"An immunostimulant nanomedicine enhances radioimmunotherapy by remodeling the tumor immunosuppressive landscape after radiotherapy","authors":"Mengwan Jiang , Mingyue Chen , Wen Zou , Yingxin Xie , Jinjin Shi , Junjie Liu , Aibing Chen , Xiu Zhao","doi":"10.1016/j.apsb.2025.11.012","DOIUrl":"10.1016/j.apsb.2025.11.012","url":null,"abstract":"<div><div>Studies have shown that radiotherapy (RT) has powerful immune-stimulating effects. However, RT-mediated distal tumor regression is rare in clinical practice. Here, with an animal experimental model, we found that RT shaped an immunosuppressive landscape characterized by a high-influx of myeloid-derived suppressor cells (MDSCs), and the induction of immunologically silent tumor apoptosis, hindering the efficacy of radioimmunotherapy. To address this issue, we developed a spatiotemporally controlled nanomedicine for remodeling the immunosuppressive tumor microenvironment (TME) post-RT. Decitabine (DAC)-loaded ferritin (Ft) were crosslinked <em>via</em> an azobenzene linker, and meanwhile encapsulated with all-trans retinoic acid (ATRA) to construct a Ft@DAC@ATRA nanoassembly (denoted as FD@ATRA), which dissociated into monodispersive Ft@DAC units in hypoxia TME. The released ATRA could eliminate immunosuppressive MDSCs, and meanwhile Ft@DAC selectively induced immunogenic pyroptosis of the tumor by targeting the transferrin receptor 1 overexpressed on the tumor to effectively activate CD8<sup>+</sup> T cells. FD@ATRA treatment reshaped the tumor immune landscape post-RT with an increase of 16.8% in tumor-infiltrating IFN-<em>γ</em><sup>+</sup>CD8<sup>+</sup> T cells. Moreover, FD@ATRA-enhanced RT remained effective in large, treatment-resistant tumors, and the inhibition rate of FD@ATRA-enhanced RT on distant tumors improved by 47% compared to the RT group alone, providing an effective therapeutic approach to improve the clinical outcomes of radioimmunotherapy.</div></div>","PeriodicalId":6906,"journal":{"name":"Acta Pharmaceutica Sinica. B","volume":"16 2","pages":"Pages 1059-1073"},"PeriodicalIF":14.6,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146177505","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-01Epub Date: 2025-11-03DOI: 10.1016/j.apsb.2025.10.046
Qian Jing , Mengnan Zhao , Yan Tang, Tao Chen, Mingyan Sun, Dandan Mi, Lan Zou, Rujing Wang, Jun Lu, Sanjun Shi
Interference with calcium homeostasis provokes tumor cell death and immune response, providing a novel direction for tumor immunotherapy as a promising cancer treatment strategy. Nevertheless, most reported Ca2+-overloaded nanoinducers encounter challenges such as intricate preparation procedures, safety concerns arising from inorganic material input, and limited anti-tumor efficiency. Herein, we synthesized a biocompatible and pH-sensitive Ca-doped cyclodextrin metal-organic framework (Ca/K-MOF) as a carrier, which was then loaded with photosensitizer hypericin (HY) via a simple one-pot synthesis to form HY@Ca/K-MOF. To enhance the stability both in vitro and in vivo, we coated HY@Ca/K-MOF with a hydrophilic layer of PEG (PEGHY@Ca/K-MOF). When exposed to 590 nm photoirradiation, PEGHY@Ca/K-MOF, with its pH-responsive dissociation, the Ca2+ and HY mediators released at the tumor site share the responsibility of triggering intracellular Ca2+ disturbances, which amplified the production of reactive oxygen species (ROS) and led to mitochondrial calcium overload through modulating mitochondrial MICU1 function. Under photocontrol, this interplay between ROS generation and mitochondrial calcium overload created a bidirectional amplification effect, where each process reinforced the other, subsequently eliciting a pyroptosis-evoked immune response. Significantly, this newly constructed delivery platform effectively suppressed both primary and distant tumors without the need for additional immunological interventions. In summary, this Ca2+-doped MOF-based nanomaterial provides a promising approach for efficient tumor photo-controlled mitochondrial Ca2+ overload-pyroptosis immunotherapy.
{"title":"A systemic immunogenic reactor leveraging modified γ-cyclodextrins for photo-controlled cancer Ca2+ interference via modulating MICU1","authors":"Qian Jing , Mengnan Zhao , Yan Tang, Tao Chen, Mingyan Sun, Dandan Mi, Lan Zou, Rujing Wang, Jun Lu, Sanjun Shi","doi":"10.1016/j.apsb.2025.10.046","DOIUrl":"10.1016/j.apsb.2025.10.046","url":null,"abstract":"<div><div>Interference with calcium homeostasis provokes tumor cell death and immune response, providing a novel direction for tumor immunotherapy as a promising cancer treatment strategy. Nevertheless, most reported Ca<sup>2+</sup>-overloaded nanoinducers encounter challenges such as intricate preparation procedures, safety concerns arising from inorganic material input, and limited anti-tumor efficiency. Herein, we synthesized a biocompatible and pH-sensitive Ca-doped cyclodextrin metal-organic framework (Ca/K-MOF) as a carrier, which was then loaded with photosensitizer hypericin (HY) <em>via</em> a simple one-pot synthesis to form HY@Ca/K-MOF. To enhance the stability both <em>in vitro</em> and <em>in vivo</em>, we coated HY@Ca/K-MOF with a hydrophilic layer of PEG (<sup>PEG</sup>HY@Ca/K-MOF). When exposed to 590 nm photoirradiation, <sup>PEG</sup>HY@Ca/K-MOF, with its pH-responsive dissociation, the Ca<sup>2+</sup> and HY mediators released at the tumor site share the responsibility of triggering intracellular Ca<sup>2+</sup> disturbances, which amplified the production of reactive oxygen species (ROS) and led to mitochondrial calcium overload through modulating mitochondrial MICU1 function. Under photocontrol, this interplay between ROS generation and mitochondrial calcium overload created a bidirectional amplification effect, where each process reinforced the other, subsequently eliciting a pyroptosis-evoked immune response. Significantly, this newly constructed delivery platform effectively suppressed both primary and distant tumors without the need for additional immunological interventions. In summary, this Ca<sup>2+</sup>-doped MOF-based nanomaterial provides a promising approach for efficient tumor photo-controlled mitochondrial Ca<sup>2+</sup> overload-pyroptosis immunotherapy.</div></div>","PeriodicalId":6906,"journal":{"name":"Acta Pharmaceutica Sinica. B","volume":"16 2","pages":"Pages 1116-1139"},"PeriodicalIF":14.6,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146177484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-01Epub Date: 2025-12-06DOI: 10.1016/j.apsb.2025.12.007
Yue Ma , Chenhe Yi , Ning Cai , Baorui Tao , Yan Geng , Weiqing Shao , Rongquan Sun , Zhenmei Chen , Yitong Li , Bo Zhang , Xiangyu Wang , Jing Lin , Wenwei Zhu , Lu Lu , Wanguang Zhang , Jinhong Chen
The susceptibility to ferroptosis partially determines the efficacy of tyrosine kinase inhibitors (TKIs) in hepatocellular carcinoma (HCC), exposing a mechanistic vulnerability that can be therapeutically exploited. The development of deuterated compounds is a promising strategy for the improvement of anti-tumor efficacy. Here, we identified HCC with higher level of ferroptosis-resistance exhibited insensitive to TKIs, which could be reversed by deuterated TKIs. Aldehyde oxidase 1 (AOX1) was screened as a critical gene mediating the responsiveness to deuterated TKIs-induced ferroptosis in HCC. The presence of a pyridyl tri-deuterated methanamide contributed to the upregulation of AOX1 in a structure-dependent manner, thereby promoting ferroptosis. Mechanistically, AOX1 inhibited sirtuin 6-mediated deacetylation of H3K9 and H3K56, leading to transcriptional activation of acyl-CoA synthetase long chain family member 5, which resulted in poly-unsaturated fatty acids hyperaccumulation-induced ferroptosis. Additionally, HCC with lower AOX1 expression conferred better efficacy to deuterated TKIs. In patient cohorts with HCC, those with lower AOX1 expression exhibited a more pronounced therapeutic response to deuterated sorafenib. Overall, the present study elucidates the mechanism by which deuterated TKIs reverse TKI resistance by promoting ferroptosis and suggests that AOX1 could serve as a biomarker to guide clinical decision-making for deuterated TKI treatment in HCC.
{"title":"Deuterium modification of tyrosine kinase inhibitors contributes to reversing ferroptosis resistance through upregulation of aldehyde oxidase 1 in hepatocellular carcinoma","authors":"Yue Ma , Chenhe Yi , Ning Cai , Baorui Tao , Yan Geng , Weiqing Shao , Rongquan Sun , Zhenmei Chen , Yitong Li , Bo Zhang , Xiangyu Wang , Jing Lin , Wenwei Zhu , Lu Lu , Wanguang Zhang , Jinhong Chen","doi":"10.1016/j.apsb.2025.12.007","DOIUrl":"10.1016/j.apsb.2025.12.007","url":null,"abstract":"<div><div>The susceptibility to ferroptosis partially determines the efficacy of tyrosine kinase inhibitors (TKIs) in hepatocellular carcinoma (HCC), exposing a mechanistic vulnerability that can be therapeutically exploited. The development of deuterated compounds is a promising strategy for the improvement of anti-tumor efficacy. Here, we identified HCC with higher level of ferroptosis-resistance exhibited insensitive to TKIs, which could be reversed by deuterated TKIs. Aldehyde oxidase 1 (AOX1) was screened as a critical gene mediating the responsiveness to deuterated TKIs-induced ferroptosis in HCC. The presence of a pyridyl tri-deuterated methanamide contributed to the upregulation of AOX1 in a structure-dependent manner, thereby promoting ferroptosis. Mechanistically, AOX1 inhibited sirtuin 6-mediated deacetylation of H3K9 and H3K56, leading to transcriptional activation of acyl-CoA synthetase long chain family member 5, which resulted in poly-unsaturated fatty acids hyperaccumulation-induced ferroptosis. Additionally, HCC with lower AOX1 expression conferred better efficacy to deuterated TKIs. In patient cohorts with HCC, those with lower AOX1 expression exhibited a more pronounced therapeutic response to deuterated sorafenib. Overall, the present study elucidates the mechanism by which deuterated TKIs reverse TKI resistance by promoting ferroptosis and suggests that AOX1 could serve as a biomarker to guide clinical decision-making for deuterated TKI treatment in HCC.</div></div>","PeriodicalId":6906,"journal":{"name":"Acta Pharmaceutica Sinica. B","volume":"16 2","pages":"Pages 802-819"},"PeriodicalIF":14.6,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146177223","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-01Epub Date: 2025-12-03DOI: 10.1016/j.apsb.2025.11.034
Haisheng He , Jianping Qi , Yi Lu , Wei Wu
Profiling in vivo release kinetics of drug nanocarriers is of high translational significance. However, this has remained unrealized due to the lack of direct methodologies to quantify either the total released or residual drugs. This study employed an indirect strategy, comparing pharmacokinetics and particokinetics, to estimate the in vivo release kinetics of paclitaxel (PTX) from intravenously administered mPEG-PDLLA polymeric micelles (PMs). Blood pharmacokinetics were profiled by chromatographically quantifying PTX, while particokinetics were determined following labeling PM particles by near-infrared fluorophores with aggregation-caused quenching properties. By monitoring the dynamic change in the PTX-to-copolymer ratio, the in vivo release of PTX from the PMs was estimated. The results revealed surprisingly rapid release, with over 88.2% and 99.0% of PTX released by 15 s and 5 min post-administration, respectively. It is concluded that PTX is released rapidly from PMs in vivo, and PMs may merely work as “solvents” to solubilize PTX rather than as carriers for targeted delivery.
{"title":"Rapid in vivo release of paclitaxel from polymeric micelles","authors":"Haisheng He , Jianping Qi , Yi Lu , Wei Wu","doi":"10.1016/j.apsb.2025.11.034","DOIUrl":"10.1016/j.apsb.2025.11.034","url":null,"abstract":"<div><div>Profiling <em>in vivo</em> release kinetics of drug nanocarriers is of high translational significance. However, this has remained unrealized due to the lack of direct methodologies to quantify either the total released or residual drugs. This study employed an indirect strategy, comparing pharmacokinetics and particokinetics, to estimate the <em>in vivo</em> release kinetics of paclitaxel (PTX) from intravenously administered mPEG-PDLLA polymeric micelles (PMs). Blood pharmacokinetics were profiled by chromatographically quantifying PTX, while particokinetics were determined following labeling PM particles by near-infrared fluorophores with aggregation-caused quenching properties. By monitoring the dynamic change in the PTX-to-copolymer ratio, the <em>in vivo</em> release of PTX from the PMs was estimated. The results revealed surprisingly rapid release, with over 88.2% and 99.0% of PTX released by 15 s and 5 min post-administration, respectively. It is concluded that PTX is released rapidly from PMs <em>in vivo</em>, and PMs may merely work as “solvents” to solubilize PTX rather than as carriers for targeted delivery.</div></div>","PeriodicalId":6906,"journal":{"name":"Acta Pharmaceutica Sinica. B","volume":"16 2","pages":"Pages 1155-1165"},"PeriodicalIF":14.6,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146177308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-01Epub Date: 2025-12-16DOI: 10.1016/j.apsb.2025.12.017
Pan Tan , Song Li , Jin Huang , Ziyi Zhou , Liang Hong
Artificial intelligence (AI) has revolutionized the design of antibodies and RNA aptamers, driving significant advancements in molecular therapeutics. In antibody design, AI enables accurate structure prediction and optimization of binding affinity, specificity, and stability, thereby accelerating the development of therapies targeting challenging antigens, such as those associated with viral infections and cancer. By integrating sequence and structural data, AI significantly reduces experimental costs and development timelines, streamlining the creation of next-generation antibody-based therapeutics. Similarly, AI has transformed RNA aptamer design, addressing long-standing challenges in structure prediction and binding optimization. AI-driven approaches allow for the rapid generation of aptamers with enhanced specificity, stability, and functional properties, expanding their potential applications in both therapeutics and diagnostics. These advancements offer scalable, cost-effective, and highly customizable solutions for precision medicine. As AI systems continue to evolve and integrate with experimental validation, they hold immense promise for developing more effective treatments for complex diseases, including cancer, autoimmune disorders, and viral infections. This marks the beginning of a new era in therapeutic innovation, where AI plays a pivotal role in addressing the challenges of modern medicine.
{"title":"Harnessing deep learning to accelerate the development of antibodies and aptamers","authors":"Pan Tan , Song Li , Jin Huang , Ziyi Zhou , Liang Hong","doi":"10.1016/j.apsb.2025.12.017","DOIUrl":"10.1016/j.apsb.2025.12.017","url":null,"abstract":"<div><div>Artificial intelligence (AI) has revolutionized the design of antibodies and RNA aptamers, driving significant advancements in molecular therapeutics. In antibody design, AI enables accurate structure prediction and optimization of binding affinity, specificity, and stability, thereby accelerating the development of therapies targeting challenging antigens, such as those associated with viral infections and cancer. By integrating sequence and structural data, AI significantly reduces experimental costs and development timelines, streamlining the creation of next-generation antibody-based therapeutics. Similarly, AI has transformed RNA aptamer design, addressing long-standing challenges in structure prediction and binding optimization. AI-driven approaches allow for the rapid generation of aptamers with enhanced specificity, stability, and functional properties, expanding their potential applications in both therapeutics and diagnostics. These advancements offer scalable, cost-effective, and highly customizable solutions for precision medicine. As AI systems continue to evolve and integrate with experimental validation, they hold immense promise for developing more effective treatments for complex diseases, including cancer, autoimmune disorders, and viral infections. This marks the beginning of a new era in therapeutic innovation, where AI plays a pivotal role in addressing the challenges of modern medicine.</div></div>","PeriodicalId":6906,"journal":{"name":"Acta Pharmaceutica Sinica. B","volume":"16 2","pages":"Pages 788-801"},"PeriodicalIF":14.6,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146177128","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-01Epub Date: 2025-12-07DOI: 10.1016/j.apsb.2025.12.006
Han Ma , Yuqi Wu , Delong Li , Haowen Sun , Yuan Xie , Shichun Zhao , Wenqian Guo , Meng Wang , Renyun Cui , Yanrong Huang , Xiankang Zhang , Jin-Yi Wan , Haiqiang Yao , Chun-Su Yuan
Obesity-prone (OP) individuals exhibit an intrinsic predisposition to obesity and associated metabolic disorders, and early intervention in this population holds significant clinical value; however, the underlying mechanisms driving this susceptibility remain largely obscure. This study enrolled 46 OP subjects without diagnosed metabolic diseases and 35 healthy controls. Our findings revealed that, despite not reaching obesity diagnoses, OP subjects exhibited significant metabolic disturbances strongly associated with gut microbiota dysbiosis. They also displayed disturbed bile acid (BA) profiles, with depleted glycodeoxycholic acid (GDCA) identified as the most potent discriminator between the OP and healthy controls. Fecal microbiota transplantation (FMT) recapitulated metabolic dysfunction and BA pool remodeling, mediated by dysregulated hepatic expression of BA synthesis genes of Cyp8a1, Cyp7a1, and Cyp7b1. Notably, FMT-OP mice also phenocopied the diminished GDCA levels observed in OP subjects. GDCA supplementation in obese mice markedly improved body weight, hepatic steatosis, and metabolic dysfunction. Mechanistically, GDCA exerted anti-obesity effects by activating the TGR5 signaling, which enhanced brown adipose tissue (BAT) thermogenesis and stimulated ileal glucagon-like peptide-1 (GLP-1) secretion, thereby ameliorating obesity and associated metabolic dysregulation. Thus, these findings indicate that gut microbiota-driven dysregulation of BA signaling, particularly impaired TGR5 activation due to diminished GDCA, underlies glycolipid metabolic dysfunction in OP individuals.
{"title":"Gut microbiota drives the metabolic dysregulation in obesity-prone individuals by impairing GDCA-mediated activation of brown adipose thermogenesis and ileal GLP-1 secretion","authors":"Han Ma , Yuqi Wu , Delong Li , Haowen Sun , Yuan Xie , Shichun Zhao , Wenqian Guo , Meng Wang , Renyun Cui , Yanrong Huang , Xiankang Zhang , Jin-Yi Wan , Haiqiang Yao , Chun-Su Yuan","doi":"10.1016/j.apsb.2025.12.006","DOIUrl":"10.1016/j.apsb.2025.12.006","url":null,"abstract":"<div><div>Obesity-prone (OP) individuals exhibit an intrinsic predisposition to obesity and associated metabolic disorders, and early intervention in this population holds significant clinical value; however, the underlying mechanisms driving this susceptibility remain largely obscure. This study enrolled 46 OP subjects without diagnosed metabolic diseases and 35 healthy controls. Our findings revealed that, despite not reaching obesity diagnoses, OP subjects exhibited significant metabolic disturbances strongly associated with gut microbiota dysbiosis. They also displayed disturbed bile acid (BA) profiles, with depleted glycodeoxycholic acid (GDCA) identified as the most potent discriminator between the OP and healthy controls. Fecal microbiota transplantation (FMT) recapitulated metabolic dysfunction and BA pool remodeling, mediated by dysregulated hepatic expression of BA synthesis genes of <em>Cyp8a1</em>, <em>Cyp7a1</em>, and <em>Cyp7b1</em>. Notably, FMT-OP mice also phenocopied the diminished GDCA levels observed in OP subjects. GDCA supplementation in obese mice markedly improved body weight, hepatic steatosis, and metabolic dysfunction. Mechanistically, GDCA exerted anti-obesity effects by activating the TGR5 signaling, which enhanced brown adipose tissue (BAT) thermogenesis and stimulated ileal glucagon-like peptide-1 (GLP-1) secretion, thereby ameliorating obesity and associated metabolic dysregulation. Thus, these findings indicate that gut microbiota-driven dysregulation of BA signaling, particularly impaired TGR5 activation due to diminished GDCA, underlies glycolipid metabolic dysfunction in OP individuals.</div></div>","PeriodicalId":6906,"journal":{"name":"Acta Pharmaceutica Sinica. B","volume":"16 2","pages":"Pages 836-853"},"PeriodicalIF":14.6,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146177197","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-02-01Epub Date: 2025-12-22DOI: 10.1016/j.apsb.2025.12.026
Sanjiang Du , Hanlin Wang , Feiyang Geng , Zongxu Zhang , Chenghao Liu , Weiyue Lu , Gang Wei
Transdermal drug delivery relies heavily on the skin permeability of therapeutic agents. In order to develop a peptide-based delivery strategy for promoting transdermal absorption, the key physicochemical factors influencing skin permeability are first identified through cell-penetrating peptides (CPPs) screening and computational simulation. Penetratin exhibits the most outstanding permeability and safety among CPPs from various origins, and positive surface patch area emerges as the key property correlated with skin permeability of the peptides. Based on these findings, a precise model to predict skin permeability of the peptides is established, leading to the computational redesign of penetratin’s amino acid sequence. The transdermal delivery efficiency of optimized penetratin derivative (589WP) is significantly improved in vitro compared with wild-type penetratin and visualized through in vivo imaging. Furthermore, the anti-metabolic drug floxuridine (FUdR) is covalently conjugated with 589WP via ester linkage, leading to accelerated FUdR release due to esterase degradation. Subsequently, this conjugate is formulated into an anhydrous gel, which significantly inhibits melanoma growth with topical application, outperforming a higher dose of free FUdR without observed skin irritancy or toxicity. The peptide prediction and design approaches established herein hold great potential for advancing transdermal drug delivery.
{"title":"Skin-penetrating peptides derived from computational simulation improve transdermal absorption and facilitate topical treatment of melanoma","authors":"Sanjiang Du , Hanlin Wang , Feiyang Geng , Zongxu Zhang , Chenghao Liu , Weiyue Lu , Gang Wei","doi":"10.1016/j.apsb.2025.12.026","DOIUrl":"10.1016/j.apsb.2025.12.026","url":null,"abstract":"<div><div>Transdermal drug delivery relies heavily on the skin permeability of therapeutic agents. In order to develop a peptide-based delivery strategy for promoting transdermal absorption, the key physicochemical factors influencing skin permeability are first identified through cell-penetrating peptides (CPPs) screening and computational simulation. Penetratin exhibits the most outstanding permeability and safety among CPPs from various origins, and positive surface patch area emerges as the key property correlated with skin permeability of the peptides. Based on these findings, a precise model to predict skin permeability of the peptides is established, leading to the computational redesign of penetratin’s amino acid sequence. The transdermal delivery efficiency of optimized penetratin derivative (589WP) is significantly improved <em>in vitro</em> compared with wild-type penetratin and visualized through <em>in vivo</em> imaging. Furthermore, the anti-metabolic drug floxuridine (FUdR) is covalently conjugated with 589WP <em>via</em> ester linkage, leading to accelerated FUdR release due to esterase degradation. Subsequently, this conjugate is formulated into an anhydrous gel, which significantly inhibits melanoma growth with topical application, outperforming a higher dose of free FUdR without observed skin irritancy or toxicity. The peptide prediction and design approaches established herein hold great potential for advancing transdermal drug delivery.</div></div>","PeriodicalId":6906,"journal":{"name":"Acta Pharmaceutica Sinica. B","volume":"16 2","pages":"Pages 1140-1154"},"PeriodicalIF":14.6,"publicationDate":"2026-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146177311","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}